Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT03978624 | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | active not recruiting | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 |
| Oct 15, 2025 |
| clinicaltrials |
| NCT00082706 | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | active not recruiting | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04046094 | Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 12 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT02202772 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder(CGC) | active not recruiting | Phase 1 / Phase 2 | 51 | Guarionex J. DecastroOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer(ABATE) | active not recruiting | Phase 2 | 46 | Deepak KilariOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04562311 | Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma | active not recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05200988 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC(Indi-Blade) | active not recruiting | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04186013 | Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer | active not recruiting | Phase 2 | 39 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT02447549 | Study of Tumour Focused Radiotherapy for Bladder Cancer(RAIDER) | active not recruiting | Phase 2 | 345 | Institute of Cancer Research, United KingdomOTHER | 3 | Jun 9, 2020 | clinicaltrials |
| NCT02489890 | CIK in Treating Patients With Bladder Cancer | active not recruiting | Phase 2 | 1,500 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 22, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Oct 16, 2025source: clinicaltrials